Page last updated: 2024-09-04

canertinib and Disease Exacerbation

canertinib has been researched along with Disease Exacerbation in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Campos, S; Charbonneau, C; Hamid, O; Hirte, H; Jordan, C; Kaldjian, EP; Lenehan, PF; Oza, A; Plante, M; Potkul, RK; Seiden, MV; Varterasian, ML	1
Bepler, G; Chiappori, A; Daud, A; Eiseman, IA; Fishman, M; Garrett, CR; Langevin, M; Lenehan, PF; Lush, R; Mahany, JJ; Munster, P; Olson, SC; Simon, GR; Sullivan, DM; Williams, CC	1

Trials

2 trial(s) available for canertinib and Disease Exacerbation

Article	Year
Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-20, Volume: 23, Issue:24 Topics: Administration, Oral; Aged; Aged, 80 and over; Disease Progression; ErbB Receptors; Female; Humans; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Oncogene Proteins v-erbB; Ovarian Neoplasms; Protein-Tyrosine Kinases; Survival Analysis; Treatment Outcome	2005
Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Aug-01, Volume: 12, Issue:15 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Predictive Value of Tests; Protein Kinase Inhibitors; Receptor, ErbB-2; Treatment Outcome	2006

Article

Year

Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-20, Volume: 23, Issue:24

Topics: Administration, Oral; Aged; Aged, 80 and over; Disease Progression; ErbB Receptors; Female; Humans; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Oncogene Proteins v-erbB; Ovarian Neoplasms; Protein-Tyrosine Kinases; Survival Analysis; Treatment Outcome

2005

Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Aug-01, Volume: 12, Issue:15

Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Predictive Value of Tests; Protein Kinase Inhibitors; Receptor, ErbB-2; Treatment Outcome

2006